Response criteria represent the standard by which the efficacy of therapeutic agents is
determined in cancer trials. The most widely used criteria are based on the anatomic …

Background Ibrutinib is approved in the EU, USA, and other countries for patients with mantle
cell lymphoma who received one previous therapy. In a previous phase 2 study with single-…

OBJECTIVE. Numerous primary bone tumors are encountered on 18 F-FDG PET/CT, and
many are FDG avid. The degree of FDG uptake in bone tumors does not necessarily reflect …

The presence of bulky disease in Hodgkin lymphoma (HL), traditionally defined with a 1-dimensional
measurement, can change a patient’s risk grouping and thus the treatment …

PURPOSE: We analyzed whether positron emission tomography (PET)/computed tomography
standardized uptake values (SUVs) after stereotactic body radiotherapy (SBRT) could …

First-order radiomic features, such as metabolic tumor volume (MTV) and total lesion
glycolysis (TLG), are associated with disease progression in early-stage classical Hodgkin …

In the present study, we evaluated the efficacy and safety of rituximab in combination with
standard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with …

Health care consumer organizations and insurance companies increasingly are scrutinizing
value when considering reimbursement policies for medical interventions. Recently, …

Murine natural killer cells (NK) express lectin-like activation and inhibitory receptors, including
the CD94/NKG2 family of receptors that bind Qa-1, and the Ly-49 family that recognizes …

Objectives Localization of ectopic ACTH‐secreting tumours causing Cushing syndrome (ECS)
is essential for clinical management, yet often difficult. [ 68 Ga]‐DOTATATE PET/CT ([ 68 …